journal
https://read.qxmd.com/read/38342103/r21-matrix-m-malaria-vaccine-a-vital-tool-in-the-arsenal-against-malaria-not-a-silver-bullet
#61
JOURNAL ARTICLE
Olivia Ngou, Romaric Nzoumbou-Boko, Pascal Bakamba, Yap Boum
No abstract text is available yet for this article.
February 8, 2024: Lancet Infectious Diseases
https://read.qxmd.com/read/38340738/combining-vaccines-optimised-supportive-care-and-therapeutics-for-ebola-virus-disease-increases-survival
#62
JOURNAL ARTICLE
William A Fischer, David A Wohl
No abstract text is available yet for this article.
February 7, 2024: Lancet Infectious Diseases
https://read.qxmd.com/read/38340737/pharmacological-innovation-and-clinical-value-of-vv116
#63
LETTER
Mengxi Jiang, Yuan Gao, Zhongjie Hu
No abstract text is available yet for this article.
February 7, 2024: Lancet Infectious Diseases
https://read.qxmd.com/read/38340736/case-fatality-risk-among-individuals-vaccinated-with-rvsv%C3%AE-g-zebov-gp-a-retrospective-cohort-analysis-of-patients-with-confirmed-ebola-virus-disease-in-the-democratic-republic-of-the-congo
#64
JOURNAL ARTICLE
Rebecca M Coulborn, Mathieu Bastard, Nicolas Peyraud, Etienne Gignoux, Francisco Luquero, Bérengère Guai, Stephane Hans Bateyi Mustafa, Elisabeth Mukamba Musenga, Steve Ahuka-Mundeke
BACKGROUND: The rVSVΔG-ZEBOV-GP vaccine constitutes a valuable tool to control Ebola virus disease outbreaks. This retrospective cohort study aimed to assess the protective effect of the vaccine against death among patients with confirmed Ebola virus disease. METHODS: In this retrospective cohort analysis of patients with confirmed Ebola virus disease admitted to Ebola health facilities in the Democratic Republic of the Congo between July 27, 2018, and April 27, 2020, we performed univariate and multivariate analyses to assess case fatality risk and cycle threshold for nucleoprotein according to vaccination status, Ebola virus disease-specific treatments (eg, mAb114 and REGN-EB3), and other risk factors...
February 7, 2024: Lancet Infectious Diseases
https://read.qxmd.com/read/38340735/persistent-sars-cov-2-infection-significance-and-implications
#65
REVIEW
Heather M Machkovech, Anne M Hahn, Jacqueline Garonzik Wang, Nathan D Grubaugh, Peter J Halfmann, Marc C Johnson, Jacob E Lemieux, David H O'Connor, Anne Piantadosi, Wanting Wei, Thomas C Friedrich
SARS-CoV-2 causes persistent infections in a subset of individuals, which is a major clinical and public health problem that should be prioritised for further investigation for several reasons. First, persistent SARS-CoV-2 infection often goes unrecognised, and therefore might affect a substantial number of people, particularly immunocompromised individuals. Second, the formation of tissue reservoirs (including in non-respiratory tissues) might underlie the pathophysiology of the persistent SARS-CoV-2 infection and require new strategies for diagnosis and treatment...
February 7, 2024: Lancet Infectious Diseases
https://read.qxmd.com/read/38335976/immunological-response-to-fractional-dose-yellow-fever-vaccine-administered-during-an-outbreak-in-kinshasa-democratic-republic-of-the-congo-results-5-years-after-vaccination-from-a-prospective-cohort-study
#66
JOURNAL ARTICLE
Reena H Doshi, Patrick K Mukadi, Rebecca M Casey, Gabriel M Kizito, Hongjiang Gao, Beatrice Nguete U, Janeen Laven, Lilliane Sabi, Didine K Kaba, Jean-Jacques Muyembe-Tamfum, Terri B Hyde, Steve Ahuka-Mundeke, J Erin Staples
BACKGROUND: In 2016, outbreaks of yellow fever in Angola and the Democratic Republic of the Congo led to a global vaccine shortage. A fractional dose of 17DD yellow fever vaccine (containing one-fifth [0·1 ml] of the standard dose) was used during a pre-emptive mass campaign in August, 2016, in Kinshasa, Democratic Republic of the Congo among children aged 2 years and older and non-pregnant adults (ie, those aged 18 years and older). 1 year following vaccination, 97% of participants were seropositive; however, the long-term durability of the immune response is unknown...
February 6, 2024: Lancet Infectious Diseases
https://read.qxmd.com/read/38335975/accumulating-evidence-on-the-long-term-immunogenicity-of-fractional-dosing-for-yellow-fever-vaccines
#67
JOURNAL ARTICLE
Aitana Juan-Giner, George Warimwe
No abstract text is available yet for this article.
February 6, 2024: Lancet Infectious Diseases
https://read.qxmd.com/read/38330976/outpacing-antiviral-resistance-new-treatments-for-influenza-virus-infection
#68
JOURNAL ARTICLE
Lynda Coughlan, Kathleen M Neuzil
No abstract text is available yet for this article.
February 5, 2024: Lancet Infectious Diseases
https://read.qxmd.com/read/38330975/safety-and-efficacy-of-onradivir-in-adults-with-acute-uncomplicated-influenza-a-infection-a-multicentre-double-blind-randomised-placebo-controlled-phase-2-trial
#69
JOURNAL ARTICLE
Zifeng Yang, Zhengtu Li, Yangqing Zhan, Zhengshi Lin, Zhonghao Fang, Xiaowei Xu, Lin Lin, Haijun Li, Zejun Lin, Changyuan Kang, Jingyi Liang, Shiwei Liang, Yongming Li, Shaoqiang Li, Xinyun Yang, Feng Ye, Nanshan Zhong
BACKGROUND: Onradivir (ZSP1273) is a novel anti-influenza A virus inhibitor. Preclinical studies show that onradivir can inhibit influenza A H1N1 and H3N2 replication and increase the survival rate of infected animals. In this study, we aimed to evaluate the safety and efficacy of three onradivir dosing regimens versus placebo in outpatients with acute uncomplicated influenza A virus infection. METHODS: We did a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial at 20 clinical sites in China...
February 5, 2024: Lancet Infectious Diseases
https://read.qxmd.com/read/38310907/will-two-doses-of-pneumococcal-conjugate-vaccine-be-enough
#70
JOURNAL ARTICLE
Fiona M Russell, Kulkanya Chokephaibulkit
No abstract text is available yet for this article.
February 1, 2024: Lancet Infectious Diseases
https://read.qxmd.com/read/38310906/persistence-of-immune-responses-of-a-self-amplifying-rna-covid-19-vaccine-arct-154-versus-bnt162b2
#71
JOURNAL ARTICLE
Yoshiaki Oda, Yuji Kumagai, Manabu Kanai, Yasuhiro Iwama, Iori Okura, Takeshi Minamida, Yukihiro Yagi, Toru Kurosawa, Pad Chivukula, Ye Zhang, Judd L Walson
No abstract text is available yet for this article.
February 1, 2024: Lancet Infectious Diseases
https://read.qxmd.com/read/38310905/invasive-pneumococcal-disease-3-years-after-introduction-of-a-reduced-1%C3%A2-%C3%A2-1-infant-13-valent-pneumococcal-conjugate-vaccine-immunisation-schedule-in-england-a-prospective-national-observational-surveillance-study
#72
JOURNAL ARTICLE
Marta Bertran, Joshua C D'Aeth, Fariyo Abdullahi, Seyi Eletu, Nick J Andrews, Mary E Ramsay, David J Litt, Shamez N Ladhani
BACKGROUND: The UK transition from a 2 + 1 to a 1 + 1 infant immunisation schedule with the 13-valent pneumococcal conjugate vaccine (PCV13) on Jan 1, 2020, coincided with the start of the COVID-19 pandemic. We describe the epidemiology of invasive pneumococcal disease (IPD) in England over 6 financial years (April 1 to March 31) between 2017-18 and 2022-23. METHODS: We used prospective national surveillance data, including serotyping and whole-genome sequencing of invasive isolates, to analyse IPD trends in England by age and financial year...
February 1, 2024: Lancet Infectious Diseases
https://read.qxmd.com/read/38310904/mucormycosis-after-cd19-chimeric-antigen-receptor-t-cell-therapy-results-of-a-us-food-and-drug-administration-adverse-events-reporting-system-analysis-and-a-review-of-the-literature
#73
REVIEW
Kathleen P L Cheok, Adrian Farrow, Deborah Springell, Maeve O'Reilly, Simon Morley, Neil Stone, Claire Roddie
Chimeric antigen receptor (CAR) T-cell therapy leads to durable remissions in relapsed B-cell cancers, but treatment-associated immunocompromise leads to a substantial morbidity and mortality risk from atypical infection. Mucormycosis is an aggressive and invasive fungal infection with a mortality risk of 40-80% in patients with haematological malignancies. In this Grand Round, we report a case of mucormycosis in a 54-year-old patient undergoing CAR T-cell therapy who reached complete clinical control of Mucorales with combined aggressive surgical debridement, antifungal pharmacotherapy, and reversal of underlying risk factors, but with substantial morbidity from extensive oro-facial surgery affecting the patient's speech and swallowing...
February 1, 2024: Lancet Infectious Diseases
https://read.qxmd.com/read/38309279/eligibility-of-patients-with-staphylococcus-aureus-bacteraemia-for-early-oral-switch
#74
LETTER
George Cooper, Heather W Dolby, Karla Berry, Clark D Russell
No abstract text is available yet for this article.
January 31, 2024: Lancet Infectious Diseases
https://read.qxmd.com/read/38307097/controlling-the-alarming-rise-in-infectious-diseases-among-children-younger-than-5-years-in-gaza-during-the-war
#75
LETTER
Amira Mohamed Taha, Hussam Mahmoud, Sarah A Nada, Samer Abuzerr
No abstract text is available yet for this article.
January 30, 2024: Lancet Infectious Diseases
https://read.qxmd.com/read/38307096/zoonotic-tuberculosis-in-the-21st-century
#76
JOURNAL ARTICLE
Shannon C Duffy, Ben Marais, Vivek Kapur, Marcel A Behr
No abstract text is available yet for this article.
January 30, 2024: Lancet Infectious Diseases
https://read.qxmd.com/read/38307095/correction-to-lancet-infect-dis-2024-published-online-jan-10-https-doi-org-10-1016-s1473-3099-23-00629-1
#77
(no author information available yet)
No abstract text is available yet for this article.
January 30, 2024: Lancet Infectious Diseases
https://read.qxmd.com/read/38301665/correction-to-lancet-infect-dis-2024-published-online-jan-18-https-doi-org-10-1016-s1473-3099-23-00742-9
#78
(no author information available yet)
No abstract text is available yet for this article.
January 29, 2024: Lancet Infectious Diseases
https://read.qxmd.com/read/38281494/emergence-of-oropouche-fever-in-latin-america-a-narrative-review
#79
REVIEW
Konrad M Wesselmann, Ignacio Postigo-Hidalgo, Laura Pezzi, Edmilson F de Oliveira-Filho, Carlo Fischer, Xavier de Lamballerie, Jan Felix Drexler
Since its discovery in 1955, the incidence and geographical spread of reported Oropouche virus (OROV) infections have increased. Oropouche fever has been suggested to be one of the most important vector-borne diseases in Latin America. However, both literature on OROV and genomic sequence availability are scarce, with few contributing laboratories worldwide. Three reassortant OROV glycoprotein gene variants termed Iquitos, Madre de Dios, and Perdões virus have been described from humans and non-human primates...
January 25, 2024: Lancet Infectious Diseases
https://read.qxmd.com/read/38246192/novel-oral-poliovirus-vaccine-type-2-is-an-important-eradication-tool-but-reaching-every-last-child-remains-vital
#80
JOURNAL ARTICLE
Larry Kotei, Ed Clarke
No abstract text is available yet for this article.
January 18, 2024: Lancet Infectious Diseases
journal
journal
20187
4
5
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.